Prostate Cancer Medical Services in China

Prostate cancer is a malignant neoplasm arising from the glandular epithelium of the prostate, predominantly affecting men over age 50. Risk factors include advancing age, family history, African ancestry, and certain genetic mutations (e.g., BRCA2). Clinical presentation may range from asymptomatic elevated serum prostate-specific antigen (PSA) to lower urinary tract symptoms, hematuria, or skeletal pain in advanced disease. Diagnosis relies on digital rectal examination, PSA testing, multiparametric MRI, and transrectal ultrasound-guided biopsy with histopathological confirmation. Staging incorporates TNM classification, Gleason score (now integrated into Grade Groups), and risk stratification (low-, intermediate-, or high-risk) to guide management. Treatment modalities include active surveillance for low-risk disease; radical prostatectomy (open, laparoscopic, or robotic-assisted); external beam radiotherapy (including intensity-modulated radiotherapy and stereotactic body radiotherapy); brachytherapy; and systemic therapies—such as androgen deprivation therapy, next-generation anti-androgens (e.g., enzalutamide), and radioligand therapy (e.g., ¹⁷⁷Lu-PSMA)—for advanced or metastatic cases.

China offers compelling advantages for international patients seeking prostate cancer care. The country hosts nationally accredited cancer centers with urologic oncology specialists trained at leading institutions worldwide and actively engaged in multinational clinical trials. State-of-the-art infrastructure includes da Vinci Xi surgical systems, MRI-linear accelerator hybrids, and PSMA PET/CT imaging—widely deployed across tier-1 hospitals in Beijing, Shanghai, and Guangzhou. Five-year biochemical recurrence-free survival after robotic prostatectomy exceeds 90% for localized disease, consistent with global benchmarks. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical standards—making high-value care accessible. As a dedicated medical tourism agency, we facilitate seamless access: verifying hospital credentials, coordinating multidisciplinary consultations, securing priority appointments, managing visa support and accommodation, and providing transparent, all-inclusive pricing—ensuring continuity of care from initial inquiry through post-treatment follow-up.

Treatment Options & Itemized Cost Breakdown: Prostate Cancer (Urology Department)

Non-Surgical / Conservative / Medication Options

*Indicated for low-risk localized disease, elderly/frail patients, or active surveillance candidates.*

• •Active Surveillance

- *Eligibility*: Gleason ≤6, PSA <10 ng/mL, clinical stage ≤T2a, <3 positive biopsy cores

- *Annual monitoring*: Digital rectal exam ($45), PSA test ($28), multiparametric MRI ($320), repeat targeted biopsy ($850) - *Total annual cost*: $1,243

• •Androgen Deprivation Therapy (ADT)

- *Eligibility*: Intermediate/high-risk localized or metastatic disease; contraindicated in severe cardiovascular disease

- *Monthly injections (e.g., goserelin)*: $185–$290 - *LHRH agonist + anti-androgen combo (6 months)*: $2,100–$3,400 - *Baseline labs (testosterone, LFTs, CBC, metabolic panel)*: $110

• •Oral Anti-Androgens (e.g., bicalutamide)

- *Monotherapy (low-volume metastatic)*: $140/month × 12 = $1,680/year

- *Pharmacy dispensing fee*: $12

Surgical / Procedural / Interventional Options

*All procedures performed in Urology Department of Grade 3A hospitals.*

• •Radical Prostatectomy (Robotic/Laparoscopic)

- *Eligibility*: Clinical stage ≤T3a, life expectancy ≥10 years, ECOG 0–1

- *Preoperative workup*: PSA ($28), mpMRI ($320), bone scan ($260), ECG + pulmonary function ($135) → $743 total - *Procedure cost*: Robotic ($8,200–$11,500); Laparoscopic ($5,900–$7,800); Open ($4,300–$5,600)

• •External Beam Radiotherapy (EBRT)

- *Eligibility*: T1–T3b N0 M0; unsuitable for surgery or patient preference

- *Simulation + planning CT/MRI*: $480 - *40-fraction IMRT course*: $6,100–$8,900 - *Weekly on-treatment labs (PSA, CBC)*: $220

• •Brachytherapy (Low-Dose Rate)

- *Eligibility*: T1–T2a, Gleason ≤7, PSA <15 ng/mL

- *Pre-implant transrectal ultrasound + dosimetry*: $1,250 - *Iodine-125 seed implantation*: $4,700–$6,300

Special / Complex Condition Options

• •Metastatic Castration-Resistant Prostate Cancer (mCRPC)

- *Abiraterone + prednisone (12 months)*: $14,200

- *Enzalutamide (12 months)*: $18,600 - *Radium-223 (6 injections)*: $12,800

• •High-Risk Locally Advanced Disease

- *Post-op radiotherapy + ADT (24 months)*: $10,400–$13,700

Quick Selection Guide

• •Age <65, fit, localized disease: Robotic prostatectomy ($9,350 avg) — optimal oncologic control.
• •Age ≥75 or significant comorbidities: Active surveillance ($1,243/yr) or ADT monotherapy ($2,100/6 mo).
• •Budget-constrained (<$5,000): Open prostatectomy ($5,000) or EBRT ($6,100 minimum).
• •High-risk/metastatic: Enzalutamide + ADT — prioritize mCRPC protocols despite higher cost ($18,600/yr).
• •Radiation-intolerant or recurrent post-RT: Salvage cryoablation ($4,800–$6,200) — urology-led, image-guided.